Hook - Thesis
RadNet pulled back sharply today to $60.68 after a run-up in recent sessions. That move creates a clearer risk-reward for buyers who want exposure to the defensive, recurring cash flow of outpatient imaging plus a leveraged upside to medical imaging AI through the companys recent Gleamer acquisition. The core trade: RadNet is a fundamentally growing services business (record Q4 revenue of $547.7 million) that is also doubling down on a fast-growing digital health opportunity. The market appears to be applying short-term technical pressure even as the business narrative improves - that mismatch is our entry.
Thesis in two lines: Buy the pullback for a mid-term swing - RadNet's outpatient imaging franchise is delivering mid-teens revenue growth, and the $270 million Gleamer buyout accelerates DeepHealths path to scale. Technicals are oversold enough to warrant a tactical long with a defined stop.
What the company does and why the market should care
RadNet operates a national network of outpatient diagnostic imaging centers that provide MRI, CT, PET, mammography and other modalities. Outpatient imaging tends to be more cost-efficient and higher margin than hospital-based imaging and benefits from demographic tailwinds - aging populations and persistent demand for diagnostic services. RadNet also runs DeepHealth, its radiology IT and AI division, which sells workflow and diagnostic support tools to radiology groups and health systems. The company reported record fourth quarter 2025 revenue of $547.7 million (up 14.8% year-over-year) and adjusted EBITDA of $87.7 million (up 16.9% YoY) - clear evidence that growth and margin progress are concurrent.
Why the Gleamer acquisition matters
On 03/02/2026 RadNet disclosed a $270 million acquisition of Gleamer, a Paris-based leader in radiology AI. Management guided 2026 imaging center revenue growth of 17-19% and digital health revenue growth of 46-56%. Bringing Gleamer into DeepHealth instantly enlarges RadNet's AI product set and addresses an attractive market - one report in the news flow projects the AI medical imaging market could approach $20 billion by 2033. If RadNet executes, DeepHealth becomes a recurring-software-like revenue stream that compounds returns on top of the steady imaging center cash flows.
Supporting the argument with the numbers
- Record Q4 revenue: $547.7 million (+14.8% YoY).
- Adjusted EBITDA Q4: $87.7 million (+16.9% YoY), indicating improving operating leverage.
- Market capitalization roughly $4.7 billion and enterprise value roughly $5.02 billion.
- Valuation multiples: EV/Sales ~2.46 and EV/EBITDA ~21.05. Price-to-sales ~2.3, price-to-book ~4.31.
- 52-week range: low $45.00, high $85.84 - today's $60.68 sits closer to the lower third of that range.
- Technicals: RSI ~35 (near oversold territory) and price below the 50-day SMA (~$71.40), suggesting the pullback has left momentum weak but potentially mean-reverting.
Valuation framing
RadNet's EV/Sales of ~2.46 and EV/EBITDA ~21 present a mixed picture. The EV/Sales multiple is not demanding for a company growing revenue in the mid-to-high teens and expanding adjusted EBITDA, especially when you consider the strategic optionality of DeepHealth post-Gleamer. EV/EBITDA at 21x is richer - it prices in profitable scale from digital health and continued margin improvement at the centers. The market is effectively paying for growth and the AI story; the pullback reduces the immediate multiple if revenue and synergy expectations are met.
Qualitatively, outpatient imaging is more defensible than many elective-service businesses because imaging is a core diagnostic step across specialties. That durability supports a premium to generic services peers, but investors should require proof that DeepHealth can meaningfully contribute recurring revenue and not just be an expensive R&D/SG&A sink in the near term.
Catalysts
- Integration milestones and initial cross-selling wins from the Gleamer acquisition announced on 03/02/2026 - early client wins or contract announcements could re-rate shares.
- Quarterly results and updated guidance - management's 2026 guidance (17-19% imaging growth; 46-56% digital health growth) gives multiple near-term check-points.
- New DeepHealth deployments and references from health systems or radiology groups - the Wichita Radiological Group win and the Wichita Operations Suite announcement are precedent-setting examples.
- Continued same-center revenue growth or margin expansion from scale efficiencies across the 407 centers - sustained adjusted EBITDA growth would validate the multiples.
Trade plan - actionable entry, stop, targets and time horizon
Trade direction: Long
Entry Price: $62.00
Stop Loss: $55.00
Target Price: $78.00
Horizon: mid term (45 trading days)
Rationale: Entering at $62.00 gives buyers room under recent intraday volatility while remaining materially below the 50-day SMA and recent highs. The $55 stop caps downside through a level that corresponds to a deeper technical support band and sits above the 52-week low of $45.00; a break below $55 would signal the pullback is broader than tactical profit-taking. The $78 target sits below the 52-week high of $85.84 but represents a >25% upside from the entry and is achievable if markets reward execution on Gleamer integration and the company reiterates or beats guidance.
Time frame: 45 trading days because this trade looks to capture re-rating or continued momentum following early integration updates and the next set of corporate announcements. If DeepHealth posts tangible contract wins or management raises guidance within that window, we expect the stock to accelerate toward the target.
Risks - what could go wrong (and a counterargument)
- Integration risk: The $270 million Gleamer acquisition is strategically attractive but costly; execution risk includes delayed product integration, customer churn, or missed cross-sell expectations. If integration becomes a near-term drag, adjusted EBITDA could suffer and the stock may underperform.
- Execution on digital health monetization: Management's digital health growth guidance is aggressive (46-56%). Failure to convert technology wins into recurring, durable revenue would undermine the AI growth story and justify a lower valuation.
- Macro and referral risk: Outpatient imaging volumes are somewhat cyclical and can be affected by economic slowdowns or changes in referral patterns. A meaningful decline in volumes would pressure revenue and margins.
- Leverage and cash flow: Free cash flow was negative recently (-$47.85 million in the trailing snapshot). If RadNet needs to fund integration or cadence of DeepHealth investments with additional leverage, equity could re-rate lower. Debt-to-equity sits around 1.0, so balance sheet management is something to monitor.
- Market-technical risk: Short interest and heavy short volume recently create the potential for volatility; a short-squeeze is possible on positive news but protracted selling can also exacerbate drawdowns.
Counterargument: One could reasonably argue the market is pricing in the worst-case execution scenario for DeepHealth - expensive acquisitions and competitive dynamics in AI could compress margins and leave RadNet as a lower-growth services operator. Under that thesis, a lower multiple is warranted and the stock could revisit the low end of its range near $45 if management disappoints on integration or organic volume trends. That risk justifies a strict stop at $55 in this trade plan.
What would change my mind
I will reassess the bullish stance if any of the following occur: management materially downgrades 2026 guidance, DeepHealth fails to produce any meaningful commercial wins or references within two quarters post-acquisition, or same-center imaging volumes trend down quarter-over-quarter in a way that indicates structural referral loss. Conversely, I would increase conviction if RadNet provides early, quantifiable Gleamer cross-sell wins, posts accelerating digital health revenue that outsizes guidance, or shows sustained adjusted EBITDA margin expansion.
Conclusion and stance
RadNet's pullback from the post-earnings run is an actionable risk-reward to a disciplined buyer. You are getting exposure to a large outpatient imaging platform generating record revenue and improving EBITDA while optionally buying into a scaled AI asset that could transform DeepHealth into a high-margin, recurring revenue stream. The trade is not without risk - integration and cash-flow dynamics matter - which is why the plan includes a firm stop at $55 and a mid-term horizon of 45 trading days to capture initial re-rating if execution checks out. Entry near $62 with a $78 target balances upside from the AI and imaging narratives against the real execution work ahead.
Key monitoring items
- Quarterly releases and any update to 2026 guidance.
- Specific Gleamer integration milestones and early client wins.
- Same-center revenue trends and adjusted EBITDA trajectory.
- Short interest and daily short volume flow as a volatility indicator.
If you're entering this trade, size it so a stop at $55 matches your risk tolerance and portfolio sizing rules - this is a medium-risk, catalyst-driven swing that pays to manage position risk tightly.